MediQuest Thera Raises $23M To Break Ground With Raynaud’s Drug

VentureWire -- MediQuest Therapeutics Inc. has secured $23 million toward a Series B to take a second shot at introducing the first drug for the autoimmune condition Raynaud's disease.